Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fostamatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK known ✓ | P43405 | 13/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 4/20 | 1.00 |
| ▸ | PLK4 | O00444 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 3/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | STK16 | O75716 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 2/20 | 1.00 |
| ▸ | IKBKE | Q14164 | 2/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 1.00 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 1.00 |
| ▸ | NEK9 | Q8TD19 | 2/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fostamatinib SCHEMBL29351337 | 1.00 | SYK (1.00) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL22164570 | 0.99 | SYK (0.99) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL16820327 | 0.99 | SYK (0.99) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL28519986 | 0.99 | SYK (0.97) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL12904057 | 0.97 | SYK (0.93) | SYKPTK2PLK4RETFLT3 | |
| Fostamatinib SCHEMBL16820330 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL2627479 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL12906324 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL10167983 | 0.96 | SYK (0.92) | SYKPTK2PLK4RETFLT3 | |
| SCHEMBL20227102 | 0.95 | SYK (0.91) | SYKPTK2PLK4RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| EP-4171534-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL Business Ltd (GB) | 2023-05-03 | — | — | EP | claimed |
| US-10088479-B2 | Biomarker and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-10-02 | — | — | US | claimed |
| EP-3191098-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040858-A1 | COMBINATIONS AND DOSING REGIMES TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-2370077-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI (FR) | 2011-10-05 | — | — | EP | claimed |
| WO-2010080563-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | WO | claimed |
| US-20260144794-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003136-A1 | SUBSTITUTED PYRIMIDINE-2, 4 -DIAMINES FOR TREATING CELL PROLIFERATIVE DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-7449458-B2 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449458-B2 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades; tyrosine kinase Syk kinase inhibitor; collagen-induced platelet activation inhibitor | RIGEL PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008064274-A1 | PRODRUG SALTS OF 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061201-A1 | METHODS FOR TREATING RENAL TUMORS USING 2,4-PYRIMIDINEDIAMINE DRUG AND PRODRUG COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144794-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | FLT3, BRAF, ERBB2 | SYK 497/4885PTK2 149/4885PLK4 835/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SYK 4313/4885PTK2 3464/4885PLK4 3311/4885 |
| US-20090012045-A1 | Methods of Treating Cell Proliferative Disorders | MKI67, RET, HRAS | SYK 3090/4885PTK2 17/4885PLK4 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.